tilt-123
Biologicalexperimental
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2020 (NCT04217473)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06961786 | Phase 1 | Jun 25, 2025 | TILT Biotherapeutics Ltd., University of Copenhagen |
| NCT06125197 | Phase 1 | Nov 30, 2023 | TILT Biotherapeutics Ltd. |
| NCT05222932 | Phase 1 | Jul 31, 2022 | Docrates Cancer Center, TILT Biotherapeutics Ltd. |
| NCT05271318 | Phase 1 | May 17, 2022 | TILT Biotherapeutics Ltd. |
| NCT04695327 | Phase 1 | Dec 31, 2020 | Docrates Cancer Center, TILT Biotherapeutics Ltd., University of Helsinki |
| NCT04217473 | Phase 1 | Jan 31, 2020 | TILT Biotherapeutics Ltd., University of Copenhagen, University of Nantes |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| TILT Biotherapeutics Ltd. | For profit | 6 | 6 | 1 | 2020 |
| Docrates Cancer Center | Academic/Hospital | 2 | 0 | 1 | 2020 |
| University of Copenhagen | Academic/Hospital | 2 | 0 | 1 | 2020 |
| University of Helsinki | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Nantes | Academic/Hospital | 1 | 0 | 1 | 2020 |
5 organizations
Page 1 / 1